CORT · Q3 revenue +64% YoY, EPS $1.01

Corcept Therapeutics reported Q3 2026 revenue of $340.5M (+64% YoY) and diluted EPS of $1.01, well above consensus of $0.84. Lifyorli revenue grew 92% QoQ to $91.4M, and the company reiterated its 2026 revenue guidance of $1.1B-$1.2B. The PDUFA date for relacorilant in Cushing's syndrome is December 17, 2026.

• Q3 2026 revenue $340.5M, up 64% from $207.6M in Q3 2025
• Diluted EPS $1.01 vs $0.16 in Q3 2025, beating consensus of $0.84
• Lifyorli revenue $91.4M, up 92% from $47.6M in Q2 2026
• Korlym and authorized generic revenue $249.1M, up 19% from Q2 2026